Trillium Therapeutics Inc.

Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. They have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat…More” signal with decoy receptors, they aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.